Holen Sie sich die Stockscreener-App
10.38
20.00%
1.73
Handel nachbörslich:
10.22
-0.16
-1.54%
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire
Team powers gene therapy mission, REGENXBIO asserts - Traders Union
The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts - Benzinga
Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Regenxbio: Q4 Earnings Snapshot - theheraldreview.com
Morgan Stanley Lowers Price Target for RGNX but Maintains Overwe - GuruFocus
REGENXBIO Q4 Earnings Call Highlights - MarketBeat
REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases - MSN
RegenXBio Earnings Call Balances Gene Therapy Risks - TipRanks
REGENXBIO (RGNX) Eyes Key Developments in 2026 Amid Robust Pipel - GuruFocus
Regenxbio stock: Clear Street reiterates Buy on gene therapy data By Investing.com - Investing.com Canada
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com
REGENXBIO (NASDAQ:RGNX) Posts Earnings Results - MarketBeat
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX - GlobeNewswire Inc.
Aug Catalysts: Is REGENXBIO Inc impacted by rising ratesQuarterly Profit Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com Nigeria
Morgan Stanley cuts Regenxbio stock price target on model updates By Investing.com - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com UK
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - marketscreener.com
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com UK
Earnings call transcript: Regenxbio misses Q4 2025 expectations, stock dips - Investing.com
REGENXBIO Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Regenxbio: Fourth Quarter Financial Overview - Bitget
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
REGENXBIO ($RGNX) Releases Q4 2025 Earnings - Quiver Quantitative
Regenxbio Q4 revenue rises but loss widens as costs increase - TradingView
Regenxbio Earnings Report: Q4 Overview - Benzinga
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
REGENXBIO (RGNX) Projected to Post Earnings on Thursday - MarketBeat
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
A Look Ahead: Regenxbio's Earnings Forecast - Benzinga
UPCOMING DEADLINE: REGENXBIO (RGNX) Securities Fraud Class Action – April 14, 2026 Lead Plaintiff Deadline - ChartMill
REGENXBIO Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRGNX - Finviz
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):